Research Progress on Yeast Expression of Therapeutic Recombinant Proteins

doi:10.19586/j.2095-2341.2025.0045

Current Biotechnology ›› 2025, Vol. 15 ›› Issue (3): 380-387.DOI: 10.19586/j.2095-2341.2025.0045

• Reviews • Previous Articles Next Articles

Research Progress on Yeast Expression of Therapeutic Recombinant Proteins

Zhaohui CUI(), Ling GUO, Xudong SHEN, Yi LIN, Lili ZHAI()

State Key Laboratory of Antibody Research & Development，Hebei Engineering Research Center of Antibody Medicine，North China Pharmaceutical Group Corporation New Drug Research and Development Co. ，Ltd. ，Shijiazhuang 052160，China

Received:2025-03-27 Accepted:2025-05-16 Online:2025-05-25 Published:2025-07-01
Contact: Lili ZHAI

酵母表达治疗性重组蛋白的研究进展

崔兆惠(), 郭玲, 沈旭东, 林毅, 翟丽丽()

华北制药集团新药研究开发有限责任公司，抗体药物研制国家重点实验室，抗体药物河北省工程研究中心，石家庄 052160

通讯作者: 翟丽丽
作者简介:崔兆惠 E-mail: zhaohuicui@126.com；
基金资助:
河北省战略性技术项目(23379901L)

Abstract

Abstract:

Therapeutic recombinant proteins， characterized by their high specificity， safety and minimal adverse reactions， play a crucial role in the clinical treatment of various diseases. Yeast， as a single-celled eukaryotic microorganism， has become the preferred host for expressing therapeutic recombinant proteins due to its similarity in protein secretion pathways with higher eukaryotes. However， bottlenecks remain in both the quality and production efficiency of yeast-expressed therapeutic recombinant proteins. The review summarized the latest advances in synthetic biology approaches to construct yeast cell with enhanced protein folding and secretion capabilities， with a focus on advanced cellular engineering strategies， including endoplasmic reticulum （ER） and protein trafficking pathway engineering， and humanization of glycosylation modification， in order to provide reference for improving the quality and yield of therapeutic recombinant proteins.

Key words: yeast, therapeutic recombinant proteins, endoplasmic reticulum, protein trafficking, humanization of glycosylation

摘要：

治疗性重组蛋白具有特异性强、安全性高、不良反应小等特点，在多种疾病的临床治疗中发挥重要作用。酵母作为一种单细胞真核微生物，与高等真核生物之间蛋白质分泌途径的相似性使其成为表达治疗性重组蛋白的首选宿主。然而，酵母表达的治疗性重组蛋白在产量和质量方面存在一些瓶颈。综述总结了合成生物学方法在构建具有增强治疗性重组蛋白折叠和分泌能力的酵母细胞的最新进展，重点关注了先进的细胞工程策略，包括内质网和蛋白质运输途径工程、糖基化的人源化改造，以期为提高治疗性重组蛋白的质量和产量提供参考。

关键词: 酵母, 治疗性重组蛋白, 内质网, 蛋白质运输, 人源化糖基化

CLC Number:

Q789

Zhaohui CUI, Ling GUO, Xudong SHEN, Yi LIN, Lili ZHAI. Research Progress on Yeast Expression of Therapeutic Recombinant Proteins[J]. Current Biotechnology, 2025, 15(3): 380-387.

崔兆惠, 郭玲, 沈旭东, 林毅, 翟丽丽. 酵母表达治疗性重组蛋白的研究进展[J]. 生物技术进展, 2025, 15(3): 380-387.

Figures/Tables 3

References 66

1	WALSH G, WALSH E. Biopharmaceutical benchmarks 2022[J]. Nat. Biotechnol., 2022, 40(12): 1722-1760.
2	PARTOW S, SIEWERS V, BJØRN S, et al.. Characterization of different promoters for designing a new expression vector in Saccharomyces cerevisiae [J]. Yeast, 2010, 27(11): 955-964.
3	HUERTAS M J, MICHÁN C. Paving the way for the production of secretory proteins by yeast cell factories[J]. Microb. Biotechnol., 2019, 12(6): 1095-1096.
4	MARTÍNEZ J L, LIU L, PETRANOVIC D, et al.. Pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation[J]. Curr. Opin. Biotechnol., 2012, 23(6): 965-971.
5	REBELLO S, ABRAHAM A, MADHAVAN A, et al.. Non-conventional yeast cell factories for sustainable bioprocesses[J/OL]. FEMS Microbiol. Lett., 2018, 365(21): 5096020[2025-05-16]. .
6	GOFFEAU A, BARRELL B G, BUSSEY H, et al.. Life with 6000 genes[J]. Science, 1996, 274(5287): 546-567.
7	THAK E J, YOO S J, MOON H Y, et al.. Yeast synthetic biology for designed cell factories producing secretory recombinant proteins[J/OL]. FEMS Yeast Res., 2020, 20(2): foaa009[2025-05-16]. .
8	KAVŠČEK M, STRAŽAR M, CURK T, et al.. Yeast as a cell factory: current state and perspectives[J/OL]. Microb. Cell Fact., 2015, 14: 94[2025-05-16]. .
9	KESIK-BRODACKA M. Progress in biopharmaceutical development[J]. Biotechnol. Appl. Biochem., 2018, 65(3): 306-322.
10	SPADIUT O, CAPONE S, KRAINER F, et al.. Microbials for the production of monoclonal antibodies and antibody fragments[J]. Trends Biotechnol., 2014, 32(1): 54-60.
11	VIEIRA GOMES A M, SOUZA CARMO T, SILVA CARVALHO L, et al.. Comparison of yeasts as hosts for recombinant protein production[J/OL]. Microorganisms, 2018, 6(2): 38[2025-05-16]. .
12	VALENZUELA P, MEDINA A, RUTTER W J, et al.. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast[J]. Nature, 1982, 298(5872): 347-350.
13	DEMAIN A L, VAISHNAV P. Production of recombinant proteins by microbes and higher organisms[J]. Biotechnol. Adv., 2009, 27(3): 297-306.
14	PAYNE T, FINNIS C, EVANS L R, et al.. Modulation of chaperone gene expression in mutagenized Saccharomyces cerevisiae strains developed for recombinant human albumin production results in increased production of multiple heterologous proteins[J]. Appl. Environ. Microbiol., 2008, 74(24): 7759-7766.
15	HUANG M, WANG G, QIN J, et al.. Engineering the protein secretory pathway of Saccharomyces cerevisiae enables improved protein production[J]. Proc. Natl. Acad. Sci. USA, 2018, 115(47): 11025-11032.
16	LODI T, NEGLIA B, DONNINI C. Secretion of human serum albumin by Kluyveromyces lactis overexpressing KlPDI1 and KlERO1[J]. Appl. Environ. Microbiol., 2005, 71(8): 4359-4363.
17	YUN C R, KONG J N, HCHUNG J, et al.. Improved secretory production of the sweet-tasting protein, brazzein, in Kluyveromyces lactis [J]. J. Agric. Food Chem., 2016, 64(32): 6312-6316.
18	GASSER B, SAUER M, MAURER M, et al.. Transcriptomics-based identification of novel factors enhancing heterologous protein secretion in yeasts[J]. Appl. Environ. Microbiol., 2007, 73(20): 6499-6507.
19	ZHANG W, ZHAO H L, XUE C, et al.. Enhanced secretion of heterologous proteins in Pichia pastoris following overexpression of Saccharomyces cerevisiae chaperone proteins[J]. Biotechnol. Prog., 2006, 22(4): 1090-1095.
20	HACKEL B J, HUANG D, BUBOLZ J C, et al.. Production of soluble and active transferrin receptor-targeting single-chain antibody using Saccharomyces cerevisiae [J]. Pharm. Res., 2006, 23(4): 790-797.
21	DE RUIJTER J C, KOSKELA E V, FREY A D. Enhancing antibody folding and secretion by tailoring the Saccharomyces cerevisiae endoplasmic reticulum[J/OL]. Microb. Cell Fact., 2016, 15: 87[2025-05-16]. .
22	QI Q, LI F, YU R, et al.. Different routes of protein folding contribute to improved protein production in Saccharomyces cerevisiae [J/OL]. mBio, 2020, 11(6): e02743-20[2025-05-21]. .
23	HOU J, OSTERLUND T, LIU Z, et al.. Heat shock response improves heterologous protein secretion in Saccharomyces cerevisiae [J]. Appl. Microbiol. Biotechnol., 2013, 97(8): 3559-3568.
24	HOU J, TYO K, LIU Z, et al.. Engineering of vesicle trafficking improves heterologous protein secretion in Saccharomyces cerevisiae [J]. Metab. Eng., 2012, 14(2): 120-127.
25	BAO J, HUANG M, PETRANOVIC D, et al.. Balanced trafficking between the ER and the Golgi apparatus increases protein secretion in yeast[J/OL]. AMB Expr., 2018, 8(1): 37[2025-05-21]. .
26	BAO J, HUANG M, PETRANOVIC D, et al.. Moderate expression of SEC16 increases protein secretion by Saccharomyces cerevisiae [J/OL]. Appl. Environ. Microbiol., 2017, 83(14): e03400-16[2025-05-21]. .
27	CHO E Y, CHEON S A, KIM H, et al.. Multiple-yapsin-deficient mutant strains for high-level production of intact recombinant proteins in Saccharomyces cerevisiae [J]. J. Biotechnol., 2010, 149(1-2): 1-7.
28	TOMIMOTO K, FUJITA Y, IWAKI T, et al.. Protease-deficient Saccharomyces cerevisiae strains for the synthesis of human-compatible glycoproteins[J]. Biosci. Biotechnol. Biochem., 2013, 77(12): 2461-2466.
29	WU M, SHEN Q, YANG Y, et al.. Disruption of YPS1 and PEP4 genes reduces proteolytic degradation of secreted HSA/PTH in Pichia pastoris GS115[J]. J. Ind. Microbiol. Biotechnol., 2013, 40(6): 589-599.
30	IDIRIS A, TOHDA H, SASAKI M, et al.. Enhanced protein secretion from multiprotease-deficient fission yeast by modification of its vacuolar protein sorting pathway[J]. Appl. Microbiol. Biotechnol., 2010, 85(3): 667-677.
31	FINNIS C J A, PAYNE T, HAY J, et al.. High-level production of animal-free recombinant transferrin from Saccharomyces cerevisiae [J/OL]. Microb. Cell Fact., 2010, 9: 87[2025-05-16]. .
32	SPIRO R G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds[J]. Glycobiology, 2002, 12(4): 43-56.
33	张小倩,张腾腾,闫攀,等.蛋白N-糖基化分析方法研究进展[J].生物技术进展,2019,9(3):246-252.
	ZHANG X Q, ZHANG T T, YAN P, et al.. Advances on the analysis methods of N-glycosylation[J]. Curr. Biotechnol., 2019, 9(3): 246-252.
34	LI H, D'ANJOU M. Pharmacological significance of glycosylation in therapeutic proteins[J]. Curr. Opin. Biotechnol., 2009, 20(6): 678-684.
35	SETHURAMAN N, STADHEIM T A. Challenges in therapeutic glycoprotein production[J]. Curr. Opin. Biotechnol., 2006, 17(4): 341-346.
36	LIU L, STADHEIM A, HAMURO L, et al.. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials[J]. Biologicals, 2011, 39(4): 205-210.
37	ALESSANDRI L, OUELLETTE D, ACQUAH A, et al.. Increased serum clearance of oligomannose species present on a human IgG1 molecule[J]. mAbs, 2012, 4(4): 509-520.
38	YU M, BROWN D, REED C, et al.. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans[J]. mAbs, 2012, 4(4): 475-487.
39	RABINOVICH G A, VAN KOOYK Y, COBB B A. Glycobiology of immune responses[J]. Ann. NY Acad. Sci., 2012, 1253: 1-15.
40	BANERJEE K, MICHAEL E, EGGINK D, et al.. Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice[J]. AIDS Res. Hum. Retrov., 2012, 28(2): 206-214.
41	DE VRIES R P, SMIT C H, DE BRUIN E, et al.. Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin[J]. J. Virol., 2012, 86(21): 11735-11744.
42	LIU L, LI H, HAMILTON S R, et al.. The impact of sialic acids on the pharmacokinetics of a PEGylated erythropoietin[J]. J. Pharm. Sci., 2012, 101(12): 4414-4418.
43	TYUEN C, STORRING P L, TIPLADY R J, et al.. Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures[J]. Br. J. Haematol., 2003, 121(3): 511-526.
44	HAMILTON S R, DAVIDSON R C, SETHURAMAN N, et al.. Humanization of yeast to produce complex terminally sialylated glycoproteins[J]. Science, 2006, 313(5792): 1441-1443.
45	BECK A, COCHET O, WURCH T. GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins[J]. Expert Opin. Drug Discov., 2010, 5(1): 95-111.
46	BOBROWICZ P, DAVIDSON R C, LI H, et al.. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose[J]. Glycobiology, 2004, 14(9): 757-766.
47	CHOI B K, BOBROWICZ P, DAVIDSON R C, et al.. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris [J]. Proc. Natl. Acad. Sci. USA, 2003, 100(9): 5022-5027.
48	JACOBS P P, GEYSENS S, VERVECKEN W, et al.. Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology[J]. Nat. Protoc., 2009, 4(1): 58-70.
49	NETT J H, STADHEIM T A, LI H, et al.. A combinatorial genetic library approach to target heterologous glycosylation enzymes to the endoplasmic reticulum or the golgi apparatus of Pichia pastoris [J]. Yeast, 2011, 28(3): 237-252.
50	DAVIDSON R C, NETT J H, RENFER E, et al.. Functional analysis of the ALG3 gene encoding the dol-P-man: Man5GlcNAc2-PP-dol mannosyltransferase enzyme of P. pastoris [J]. Glycobiology, 2004, 14(5): 399-407.
51	LIU L, GOMATHINAYAGAM S, HAMURO L, et al.. The impact of glycosylation on the pharmacokinetics of a TNFR2: fc fusion protein expressed in glycoengineered Pichia pastoris [J]. Pharm. Res., 2013, 30(3): 803-812.
52	DE POURCQ K, TIELS P, VAN HECKE A, et al.. Engineering Yarrowia lipolytica to produce glycoproteins homogeneously modified with the universal Man3GlcNAc2 N-glycan core[J/OL]. PLoS ONE, 2012, 7(6): e39976[2025-05-16]. .
53	DE POURCQ K, VERVECKEN W, DEWERTE I, et al.. Engineering the yeast Yarrowia lipolytica for the production of therapeutic proteins homogeneously glycosylated with Man₈GlcNAc₂ and Man₅GlcNAc₂ [J/OL]. Microb. Cell Fact., 2012, 11: 53[2025-05-16]. .
54	ARICO C, BONNET C, JAVAUD C. N-glycosylation humanization for production of therapeutic recombinant glycoproteins in Saccharomyces cerevisiae [J]. Methods Mol. Biol., 2013, 988: 45-57.
55	CHEON S A, KIM H, BOH D, et al.. Remodeling of the glycosylation pathway in the methylotrophic yeast Hansenula polymorpha to produce human hybrid-type N-glycans[J]. J. Microbiol., 2012, 50(2): 341-348.
56	VERVECKEN W, KAIGORODOV V, CALLEWAERT N, et al.. In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia pastoris [J]. Appl. Environ. Microbiol., 2004, 70(5): 2639-2646.
57	TANAKA N, KAGAMI A, HIRAI K, et al.. The fission yeast gmn2(+) gene encodes an ERD1 homologue of Saccharomyces cerevisiae required for protein glycosylation and retention of luminal endoplasmic reticulum proteins[J]. J. Gen. Appl. Microbiol., 2021, 67(2): 67-76.
58	UEDA K, SHIMABUKU A M, KONISHI H, et al.. Functional expression of human P-glycoprotein in Schizosaccharomyces pombe [J]. FEBS Lett., 1993, 330(3): 279-282.
59	WATANASRISIN W, IWATANI S, OURA T, et al.. Identification and characterization of Candida utilis multidrug efflux transporter CuCdr 1p[J/OL]. FEMS Yeast Res., 2016, 16(4): fow042[2025-05-16]. .
60	NETT J H, COOK W J, CHEN M T, et al.. Characterization of the Pichia pastoris protein-O-mannosyltransferase gene family[J/OL]. PLoS ONE, 2013, 8(7): e68325[2025-05-16]. .
61	LOIBL M, STRAHL S. Protein O-mannosylation: what we have learned from baker's yeast[J]. Biochim. Biophys. Acta, 2013, 1833(11): 2438-2446.
62	CUKAN M C, HOPKINS D, BURNINA I, et al.. Binding of DC-SIGN to glycoproteins expressed in glycoengineered Pichia pastoris [J]. J. Immunol. Methods, 2012, 386(1-2): 34-42.
63	AHLÉN G, STRINDELIUS L, JOHANSSON T, et al.. Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses[J/OL]. PLoS ONE, 2012, 7(10): e46959[2025-05-16]. .
64	ARGYROS R, NELSON S, KULL A, et al.. A phenylalanine to serine substitution within an O-protein mannosyltransferase led to strong resistance to PMT-inhibitors in Pichia pastoris [J/OL]. PLoS ONE, 2013, 8(5): e62229[2025-05-16]. .
65	MEASE P, STRAND V, SHALAMBERIDZE L, et al.. A phase Ⅱ, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate[J]. Ann. Rheum. Dis., 2012, 71(7): 1183-1189.
66	CHIGIRA Y, OKA T, OKAJIMA T, et al.. Engineering of a mammalian O-glycosylation pathway in the yeast Saccharomyces cerevisiae: production of O-fucosylated epidermal growth factor domains[J]. Glycobiology, 2008, 18(4): 303-314.

类别	治疗性重组蛋白名称	生产公司	表达系统	治疗应用
血液因子	人血清白蛋白	英国Albumedix公司	酿酒酵母	生物药物和疫苗的稳定剂
	重组凝血因子􀃼 A亚基	丹麦诺和诺德公司	酿酒酵母	先天性􀃼 A亚基缺乏症
	重组人组织型纤溶酶原激活剂	德国拜耳医药公司	酿酒酵母	与肝素相关的抗凝治疗
	重组水蛭素	德国赫斯特公司	酿酒酵母	预防静脉血栓形成
	血浆激肽释放酶抑制剂	美国德纳维制药公司	毕赤酵母	预防遗传性血管性水肿
	重组人白介素-11	杭州九源基因工程股份有限公司	毕赤酵母	血小板减少
	重组人表皮生长因子凝胶	桂林华诺威基因药业股份有限公司	酵母	皮肤溃疡、烧伤
	重组人表皮生长因子滴眼液	桂林华诺威基因药业股份有限公司	酵母	角膜疾病
	重组人干扰素α2b	上海腾瑞制药股份有限公司	酵母	病毒感染、肿瘤
重组激素	胰岛素	丹麦诺和诺德公司	酿酒酵母	糖尿病
	生长激素	德国BioPartner公司	酿酒酵母	生长激素缺乏
	胰高血糖素样肽-1类似物	丹麦诺和诺德公司	酿酒酵母	2型糖尿病
	胰高血糖素	丹麦诺和诺德公司	酿酒酵母	低血糖症
重组疫苗	重组乙型肝炎疫苗	德国默克公司	酿酒酵母	预防乙型肝炎
	重组四价人乳头瘤病毒疫苗	美国默沙东公司	酿酒酵母	预防由HPV病毒引起的疾病
	重组九价人乳头瘤病毒疫苗	德国默克公司	酿酒酵母	预防由HPV病毒引起的疾病
重组酶	尿酸氧化酶	法国赛诺菲公司	酿酒酵母	高尿酸血症
融合蛋白	GLP-1受体激动剂	英国葛兰素史克公司	酿酒酵母	2型糖尿病

类别	治疗性重组蛋白名称	生产公司	表达系统	治疗应用
血液因子	人血清白蛋白	英国Albumedix公司	酿酒酵母	生物药物和疫苗的稳定剂
	重组凝血因子􀃼 A亚基	丹麦诺和诺德公司	酿酒酵母	先天性􀃼 A亚基缺乏症
	重组人组织型纤溶酶原激活剂	德国拜耳医药公司	酿酒酵母	与肝素相关的抗凝治疗
	重组水蛭素	德国赫斯特公司	酿酒酵母	预防静脉血栓形成
	血浆激肽释放酶抑制剂	美国德纳维制药公司	毕赤酵母	预防遗传性血管性水肿
	重组人白介素-11	杭州九源基因工程股份有限公司	毕赤酵母	血小板减少
	重组人表皮生长因子凝胶	桂林华诺威基因药业股份有限公司	酵母	皮肤溃疡、烧伤
	重组人表皮生长因子滴眼液	桂林华诺威基因药业股份有限公司	酵母	角膜疾病
	重组人干扰素α2b	上海腾瑞制药股份有限公司	酵母	病毒感染、肿瘤
重组激素	胰岛素	丹麦诺和诺德公司	酿酒酵母	糖尿病
	生长激素	德国BioPartner公司	酿酒酵母	生长激素缺乏
	胰高血糖素样肽-1类似物	丹麦诺和诺德公司	酿酒酵母	2型糖尿病
	胰高血糖素	丹麦诺和诺德公司	酿酒酵母	低血糖症
重组疫苗	重组乙型肝炎疫苗	德国默克公司	酿酒酵母	预防乙型肝炎
	重组四价人乳头瘤病毒疫苗	美国默沙东公司	酿酒酵母	预防由HPV病毒引起的疾病
	重组九价人乳头瘤病毒疫苗	德国默克公司	酿酒酵母	预防由HPV病毒引起的疾病
重组酶	尿酸氧化酶	法国赛诺菲公司	酿酒酵母	高尿酸血症
融合蛋白	GLP-1受体激动剂	英国葛兰素史克公司	酿酒酵母	2型糖尿病

	治疗性重组蛋白名称	生产公司	表达系统	所处阶段	治疗应用
重组疫苗	四价重组诺如病毒疫苗	安徽智飞龙科马生物制药有限公司	毕赤酵母	临床Ⅲ期	预防诺如病毒导致的胃肠炎
	重组肠道病毒71型疫苗	重庆博唯佰泰生物制药有限公司	汉逊酵母	临床Ⅰ期	预防手足口病和肠道病毒感染
	重组十一价人乳头瘤病毒疫苗	北京生物制品研究所有限责任公司	汉逊酵母	临床Ⅲ期	人乳头瘤病毒感染
	重组十五价人乳头瘤病毒疫苗	重庆博唯佰泰生物制药有限公司	汉逊酵母	临床Ⅱ期	预防由HPV病毒引起的疾病
融合蛋白	重组人血清白蛋白-干扰素α2a融合蛋白	解放军军事医学科学院生物工程研究所	酵母	临床Ⅰ期	慢性乙型肝炎
	重组人胰高血糖素样肽-1类似物融合蛋白	江苏泰康生物医药有限公司	酵母	临床Ⅰ期	2型糖尿病
	人血清白蛋白-人粒细胞集落刺激因子（Ⅰ）融合蛋白	迈威（上海）生物科技股份有限公司	酵母	申请上市	化疗引起的发热性中性粒细胞减少
抗体	重组抗IL-4Rα单域抗体	上海洛启生物医药技术有限公司	毕赤酵母	临床Ⅱ期	哮喘、慢性阻塞性肺疾病

	治疗性重组蛋白名称	生产公司	表达系统	所处阶段	治疗应用
重组疫苗	四价重组诺如病毒疫苗	安徽智飞龙科马生物制药有限公司	毕赤酵母	临床Ⅲ期	预防诺如病毒导致的胃肠炎
	重组肠道病毒71型疫苗	重庆博唯佰泰生物制药有限公司	汉逊酵母	临床Ⅰ期	预防手足口病和肠道病毒感染
	重组十一价人乳头瘤病毒疫苗	北京生物制品研究所有限责任公司	汉逊酵母	临床Ⅲ期	人乳头瘤病毒感染
	重组十五价人乳头瘤病毒疫苗	重庆博唯佰泰生物制药有限公司	汉逊酵母	临床Ⅱ期	预防由HPV病毒引起的疾病
融合蛋白	重组人血清白蛋白-干扰素α2a融合蛋白	解放军军事医学科学院生物工程研究所	酵母	临床Ⅰ期	慢性乙型肝炎
	重组人胰高血糖素样肽-1类似物融合蛋白	江苏泰康生物医药有限公司	酵母	临床Ⅰ期	2型糖尿病
	人血清白蛋白-人粒细胞集落刺激因子（Ⅰ）融合蛋白	迈威（上海）生物科技股份有限公司	酵母	申请上市	化疗引起的发热性中性粒细胞减少
抗体	重组抗IL-4Rα单域抗体	上海洛启生物医药技术有限公司	毕赤酵母	临床Ⅱ期	哮喘、慢性阻塞性肺疾病

[1]	Jiasheng BAO, Bingzhen PAN, Qiwu QIAO, Huizhi LIU, Suhua PAN. Advances in Yeast Bioactive Substances and Their Cosmetic Efficacy [J]. Current Biotechnology, 2023, 13(3): 345-352.
[2]	ZHANG Rongxue§, SUN Yue§, SU Jingping, WANG Shengjun, LIU Yanqing, TONG Hui, SUN Linjing*. Progress on Plant Endoplasmic Reticulum Stress [J]. Curr. Biotech., 2021, 11(3): 289-297.
[3]	JIN Tong, CHEN Cheng. Research Progress on the Endoplasmic Reticulum Stress and its Mechanism in Diabetic Nephropathy [J]. Curr. Biotech., 2021, 11(1): 40-46.
[4]	ZHANG Xiangxiang, TENG Yantong, CHEN Tao^*. Research on AtEXD Participating in Response to Salt Stress in Plant [J]. Curr. Biotech., 2021, 11(1): 61-68.
[5]	LI Yanhu, NIU Yaoxing, LIU Xiaoxia, GUO Juan, DENG Zhanrui, YUN Jianmin*. Optimization of Freeze-drying Microbial Agent Preparation of Direct Vat Aroma-enhancing Yeast Starter for Jiangshui Production [J]. Curr. Biotech., 2018, 8(5): 441-449.
[6]	WANG Ting, GE Huai-Na, GUO Hong*. Progress on Application of Yeast Two-hybrid Technique [J]. Curr. Biotech., 2015, 5(5): 392-396.
[7]	ZHANG Yun-peng, WEN Tong, JIANG Wei*. The Research Progress of Escherichia coli Expression Systems and Yeast Expression Systems [J]. Curr. Biotech., 2014, 4(6): 389-393.
[8]	CHANG Liang, LIU Xiao-zhi, MENG Ya-juan, MA Zhi-jun, GAO Jian. Progress in Engineering of Yeast Secretion System [J]. Curr. Biotech., 2013, 3(3): 185-189.

Research Progress on Yeast Expression of Therapeutic Recombinant Proteins

酵母表达治疗性重组蛋白的研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 66

Related Articles 8

Recommended Articles

Metrics

Comments